Webinar: Biotech Warriors Against COVID-19

June 23, 2020 June 23, 2020
3:00PM - 4:00PM Online via Zoom Webinar

Do you know Singapore is home to many promising biotech companies, who have made inroads to the global stage? Biotech companies are the warriors in our battle against COVID-19. This webinar will provide an opportunity to be introduced to some of our finest homegrown warriors. They will share about their journey and solutions to the COVID-19 battle. Who knows? There could be an opportunity for you to be part of their journey!

The session will be moderated by Dr. Helmut M. Schuehsler, Chairman & CEO, TVM Capital Healthcare Partners, who will lead 3 invited companies to share more on their latest developments.

3:00PM      Introduction
3:05PM      Overview of the Healthcare Landscape by Dr. Helmut M. Schuehsler, Chairman & CEO, TVM Capital Healthcare Partners
3:15PM      Sharing Session by our Biotech Warriors; ACM Biolabs, Acumen Research Laboratories and Lucence
3:30PM      Panel and Q&A on Challenges and Trends in light of COVID-19
4:00PM      Thank You & End


Dr. Schuehsler started his investment management career at Horizonte Venture Management in Vienna, Austria, and joined TVM Capital in Munich in 1990. During his tenure with the TVM Capital group of companies, Dr. Schuehsler started biotech investing in Germany and made TVM Capital the leading and largest life science investor in Germany, led the development of the firm into one of the leading pan-European investors and started the life science activities in the Boston office in 1998. Dr. Schuehsler has been the deal leader on more than 35 direct investments in life science and healthcare companies in Europe, the U.S., the Middle East and India. In total he has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health market, and more than 50 IPOs and 30 M&A exit transactions in the portfolio.

Currently he is chairman of healthcare growth companies, Bourn Hall International (Dubai, Al Ain) and Manzil Health Care Services (Abu Dhabi, Dubai, NE, Riyadh, Cairo), and serves as a director at Cambridge Medical and Rehabilitation Center (Abu Dhabi, Al Ain, Dhahran). He also is a director at the F-star Group of Companies (Boston, Vienna, and Cambridge, UK), bispecific antibody companies with a focus on immuno-oncology and a board member of Apeiron Biologics, Vienna. Previously he held the positions of interim CEO and chairman at ProVita International Medical Center, which saw a hugely successful exit to NMC Health plc in mid-2015.

Dr. Nallani obtained his PhD in Germany before doing postdoctoral work in Holland and finally moved to live and work in Singapore. He spent over 15 years developing artificial cell membrane technology, and founded ACM Biolabs Pte Ltd in 2013. He has led the company to numerous awards and recognition for innovation. Madhavan also held an Assistant Professor position at Nanyang Technological University (NTU), Singapore, co-managing the Centre of Biomimetic Sensor Science (CBSS).

Despite much hype in the news the world has a major problem in getting a COVID-19 vaccine. Traditional technologies are not suited to responding quickly to pandemics, while the companies making the news with “promising new technologies in clinical trials” (e.g. Inovio with its DNA technology and Moderna and BioNtech with their mRNA platform) have spent more than a decade and billions of dollars but are yet to achieve any approved vaccine. ACM Biolabs uses its proprietary polymersomes to deliver recombinant proteins (a proven technology) efficiently to the immune system to induce excellent protection against diseases. We have extensive experience in coronavirus vaccines: we have been working on a veterinary vaccine against a highly contagious coronavirus in pigs since 2014 and expect to get a US license for that product this year, we also have promising data for COVID-19.

Trained in Singapore, USA and Canada, Dr. Ong is versatile in many fields of biomedical sciences, with skills in assay development, clinical studies, manufacturing and clinical laboratory testing. She has an interesting career as a highly-published academic, then joined a major pharmaceutical company and then founded Acumen Research Labs. She is also experienced in technology transfer by IP licensing; Acumen successfully licensed Acumen’s technology in a sepsis host response test to a German listco, Curetis GmbH in 2015 and formed a joint venture with Q&M Dental Group in 2020. She had been very active in service to the industry via committee work trade associations and sharing of insights invited by media.

Acumen is a fully-integrated molecular diagnostics company with competencies in discovery, production development, manufacturing, clinical laboratory testing and commercialization. The company focuses on major infectious diseases including sepsis, pneumonia and COVID-19. The Acu-CoronaTM RT-PCR COVID-19 tests are sold globally. Acumen has a subsidiary in Suzhou (China) and is preparing for operations in Japan. COVID-19 is a novel virus, science and technology will play a big role in intercepting it and shaping policies to respond to it, including testing, treatment and developing vaccines. We put in everything we have learnt over the years and will continue to innovate, and put to use the new ideas in Industry 4.0.

Dr Min-Han Tan is the founding CEO and Medical Director of Lucence. Trained as a medical oncologist and clinical cancer geneticist at the National Cancer Centre Singapore and the Cleveland Clinic, Dr. Tan founded Lucence to achieve the vision of a world without avoidable cancer deaths. Lucence is a precision oncology company headquartered in California and Singapore, supplying liquid biopsy testing worldwide through a central CAP and CLIA-licensed laboratory.


We regret that we are unable to refund you once your registration is confirmed. Please send a replacement if there are any last minute changes to your schedule and inform us at least 2 working days prior. A no-show fee equivalent to the registration fee will be imposed for those who have registered but payment not received by us. SVCA Full Corporate Members are applicable for the complimentary/ member's rate seat with the provision that membership fees have been paid prior in full. SVCA Associate Members are applicable for the member's rate with the provision that membership fees have been paid prior in full. Please note that information collected may be shared with 3rd parties such as partners and/ or sponsors. SVCA may (at its sole discretion) change the format, speakers, participants, content, venue location and programme or any other aspect of the event at any time and for any reason, whether or not due to a Force Majeure Event, in each case without liability. Photos and videos may be taken of the event for marketing purposes. Thank you for your co-operation.


TEL: +65 6224 7001